Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruxolitinib vs. Allogeneic SCT in Myelofibrosis (MMM 02)
NCT03333187Phase 2Active, not recruiting
- Sponsor
- University Medical Center Hamburg-Eppendorf
- Start
- Dec 2016
- Primary completion
- Oct 2024
- Countries
- 1
01
Overview
A Phase 2 trial of ruxolitinib in myelofibrosis (MF), sponsored by University Medical Center Hamburg-Eppendorf. Started Dec 2016; status: active, not recruiting.
02
Drugs
03
Conditions
myelofibrosis (MF)
Beyond the preview
Go deeper on NCT03333187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03333187.